GPRC5D CAR T cells (OriCAR-017) in patients with relapsed or refractory multiple myeloma (POLARIS): a first-in-human, single-centre, single-arm, phase 1 trial

Overview of attention for article published in The Lancet Haematology, February 2023

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
Among the highest-scoring outputs from this source (#14 of 1,334)
High Attention Score compared to outputs of the same age (99th percentile)
High Attention Score compared to outputs of the same age and source (97th percentile)

So far, Altmetric has seen 55 X posts from 45 X users, with an upper bound of 631,312 followers.

RT @Transplant_Doc: GPRC5D CAR-T cells (OriCAR-017) in RRMM (POLARIS), Phase I trial. N=10, 5 with prior anti-BCMA CAR-T. CRS: 100%, NT: ze…

RT @Transplant_Doc: GPRC5D CAR-T cells (OriCAR-017) in RRMM (POLARIS), Phase I trial. N=10, 5 with prior anti-BCMA CAR-T. CRS: 100%, NT: ze…

RT @Transplant_Doc: GPRC5D CAR-T cells (OriCAR-017) in RRMM (POLARIS), Phase I trial. N=10, 5 with prior anti-BCMA CAR-T. CRS: 100%, NT: ze…

RT @Transplant_Doc: GPRC5D CAR-T cells (OriCAR-017) in RRMM (POLARIS), Phase I trial. N=10, 5 with prior anti-BCMA CAR-T. CRS: 100%, NT: ze…

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity, including 51 additional X posts.